Regeneron and Partner Announced Positive First Trial Results of Odyssey

Regeneron and its partner Sanofi announced positive results in the first trial of their extensive Phase III ODYSSEY program (12 trials in total) for alirocumab (REGN-727), which targets PCSK9 to lower LDL (or “bad”) cholesterol. Alirocumab showed a 47.2% reduction in LDL levels from baseline over 24 weeks in patients with primary hypercholesterolemia and moderate…

Read More

5 Stocks Under Wall Street’s Radar: CEVA Inc. (NASDAQ:CEVA), JD.com, Inc. (NASDAQ:JD), AMZG, General Motors Company (NYSE:GM), Safeguard Scientifics, Inc. (NYSE:SFE)

CEVA, Inc. (NASDAQ:CEVA), will announce results for the third quarter ended September 30, 2014 on October 30th, before the NASDAQ market opens. CEVA Inc. (NASDAQ:CEVA) in last trading activity moved up 2.14% to close at $14.34. Company weekly performance is 8.55% while its quarterly performance stands at 0.77%. CEVA Inc. (NASDAQ:CEVA) is -24.25% away from…

Read More
Home